ArticleEuropean journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery2020
Editor's Choice - Long Term Survival after Femoropopliteal Artery Revascularisation with Paclitaxel Coated Devices: A Propensity Score Matched Cohort Analysis.
Article in European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 35 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
IDOMENEO: Multimethodical and Multistage Registry-based Longitudinal Study Project to Collect Primary Registry Data and Health Insurance Claims Data of Patients Invasively Treated for Peripheral Artery Disease (PAD) in Germany
Assessing Best Medical Treatment Patterns of Patients With Symptomatic Peripheral Arterial Occlusive Disease in Germany - A GermanVasc Study
Real-World Safety Analysis of Paclitaxel Devices Used for the Treatment of Peripheral Arterial Disease
Who cites it
35 citing papers in PubMed, 5 syntheses or guidelines pooled it, 119 citations in OpenAlex.
- Liquid Drug Delivery Approaches for the Treatment of Occlusive Arterial Disease: A Systematic Review.Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists · 2024Pooled it
- Robustness of Longitudinal Safety and Efficacy After Paclitaxel-Based Endovascular Therapy for Treatment of Femoro-Popliteal Artery Occlusive Disease: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials.Annals of vascular surgery · 2024Pooled it
- Endovascular revascularization strategies for aortoiliac and femoropopliteal artery disease: a meta-analysis.European heart journal · 2023Pooled it
- Safety of paclitaxel-coated devices in the femoropopliteal arteries: A systematic review and meta-analysis.PloS one · 2022Pooled it
- Update on paclitaxel for femoral-popliteal occlusive disease in the 15 months following a summary level meta-analysis demonstrated increased risk of late mortality and dose response to paclitaxel.Journal of vascular surgery · 2021Pooled it
- Long-Term Follow-up and Mortality Rate of Patients of the Randomized Freeway Stent Study.Cardiovascular and interventional radiology · 2024Trial
- Paclitaxel Efficacy in Dialysis-Dependent Peripheral Artery Disease: A National Cohort Analysis.Journal of the American Heart Association · 2026Article
- Proximal plaque cap morphology in femoropopliteal occlusion affects the primary patency of endovascular therapy: a CT angiography cohort study.La Radiologia medica · 2026Article
- Major Adverse Limb Events and Death After Successful Endovascular Revascularization: BEST-CLI Trial.Journal of the Society for Cardiovascular Angiography & Interventions · 2026Article
- Sirolimus coated balloons in peripheral arterial disease, what's next?Cardiovascular diagnosis and therapy · 2025Article
- Early outcomes of drug-coated balloon angioplasty and stent placement for the treatment of iliac artery lesions.Frontiers in surgery · 2025Article
- Introducing and utilizing innovative technologies in health care systems: a country comparison for peripheral drug-eluting stents in Germany and the USA.Frontiers in public health · 2025Review
- Drug-eluting devices for lower limb peripheral arterial disease.EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology · 2024Review
- Consensus minimum core data elements adapted to peripheral vascular intervention in the drug-eluting era: Consensus report from the Registry Assessment of Peripheral Interventional Devices (RAPID) Pathways "LEAN" working group.Journal of vascular surgery · 2023Article
- The Role of Drug-Coated Balloon in Haemodialysis Arteriovenous Fistula Stenosis Management.Cardiovascular and interventional radiology · 2023Review
- Patient and limb outcomes 10 years after endovascular revascularization of the superficial femoral artery for peripheral artery disease: The Boston Femoral Artery Endovascular Revascularization Outcomes (Boston FAROUT) study.Vascular medicine (London, England) · 2023Article
- Real-World Safety Analysis of Paclitaxel Devices Used for the Treatment of Peripheral Artery Disease.Journal of vascular and interventional radiology : JVIR · 2023Article
- Repetition of Paclitaxel-Coated Devices for the Treatment of Lower Extremity Artery Disease: Mortality Outcomes and Predictors.Acta Cardiologica Sinica · 2023Article
- Editor's Choice - Real World Study of Mortality After the Use of Paclitaxel Coated Devices in Peripheral Vascular Intervention.European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery · 2023Article
- Algorithm of Femoropopliteal Endovascular Treatment.Medicina (Kaunas, Lithuania) · 2022Article
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Commented on by
Authors and funding
10 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe aim of this study was to determine the survival of patients after use of paclitaxel coated devices (PCX), as a recent meta-analysis of randomised trials reported higher mortality in patients treated with PCX balloons and stents
methodsA retrospective health insurance claims analysis of patients covered by the second largest insurance fund in Germany, BARMER, was used to identify index femoropopliteal arterial interventions between 1 January 2010 and 31 December 2018. To ensure first PCX exposure, patients with prior deployment of PCX were excluded. The study cohort was stratified into patients with chronic limb threatening ischaemia (CLTI) and intermittent claudication (IC), then into balloons vs. stents cohorts. Within each stratum PCX were compared with uncoated devices. Propensity score matching was used to balance the study groups. Survival was evaluated using the Kaplan-Meier method and Cox regression.
resultsThere were 37 914 patients (mean age 73.3 years; 48.8% female) included in the study. The annual proportion of PCX use increased from 3% to 39% during the study period for CLTI and from 4% to 48% for IC (both p < .001). Paclitaxel coated balloons and stents were associated with improved overall survival (hazard ratio [HR] 0.83, 95% confidence interval [CI] 0.77-0.90), amputation free survival (HR 0.85, 95% CI 0.78-0.91), and freedom from major cardiovascular events (HR 0.82, 95% CI 0.77-0.89) vs. uncoated devices at five years for CLTI. In IC cohort, mortality was significantly lower after using drug coated balloons (DCB) (HR 0.87, 95% CI 0.76-0.99) or combined DCB and drug eluting stents (HR 0.88, 95% CI 0.80-0.98).
conclusionIn this large health insurance claims analysis, rapid adoption of PCX, higher long term survival, better amputation free survival, and lower rates of major cardiovascular events were seen after their use for the treatment of CLTI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.